Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • Strides Pharma reports...

    Strides Pharma reports revenue of Rs 718 crore for Q2

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-10-27T09:32:44+05:30  |  Updated On 27 Oct 2019 9:32 AM IST
    Strides Pharma reports revenue of Rs 718 crore for Q2

    EBITDA margins stood at 21 per cent, up by 300 basis point quarter-on-quarter and 1,170 bps year-on-year. EBITDA margin expansion was led by good performance in the regulated markets, said Strides Pharma.


    Bengaluru: Strides Pharma Science on Friday reported consolidated revenues at Rs 718 crore during the July to September quarter, demonstrating a 37 per cent year-on-year growth.


    In Q2 FY19, it had reported revenues at Rs 524 crore while they totalled Rs 688 crore in the first quarter of current fiscal (Q1 FY20).


    The consolidated earnings before interest, tax, depreciation and amortisation (EBITDA) totalled Rs 150 crore, up 210 per cent year-on-year and 22 per cent quarter-on-quarter.


    EBITDA margins stood at 21 per cent, up by 300 basis point quarter-on-quarter and 1,170 bps year-on-year. EBITDA margin expansion was led by good performance in the regulated markets, said the company.


    "This quarter's financial results validate our reset strategy, with an enhanced focus on growth and margin opportunities from regulated markets," said Group CEO and Managing Director Arun Kumar.


    "These markets now contribute to over 85 per cent of our revenues, establishing the strength of our operating model built around diversified markets and carefully selected product portfolio," he said in a statement.


    In spite of underperforming emerging markets and continued R&D spend, the group EBITDA margins exceeded 20 per cent for the first time in many quarters, said Kumar.


    Read Also: New batch of Strides Pharma Ranitidine available for sale in Australia


    "But the challenges of institutional business and emerging markets persist. We continue to evolve on our course-corrected strategy, which will deliver positive outcomes in the near term."


    Strides Pharma Science mainly operates in the regulated markets and has an 'In Africa For Africa' strategy along with an institutional business to service donor-funded markets.


    The company's global manufacturing sites are located at Bengaluru, Pondicherry and Chennai in India, Singapore, Milan in Italy, Nairobi in Kenya and Florida in the United States. It focuses on 'difficult to manufacture' products that are sold in over 100 countries.


    Read Also: Strides Pharma clears USFDA inspection of Alathur facility

    Arun KumarEBITDAFY19pharmapharma newspharma news indiaQ2 resultsStrides Pharmastrides pharma q2strides revenue
    Source : ANI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok